A form of the drug, formerly known by the ONCONASE trademark and as "Onconase for injection", was previously evaluated by the US Food and Drug Administration for over twenty years in numerous clinical trials.
and Alfacell Corporation have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to ONCONASE (ranpirnase) from Alfacell.
It is important to realize that Onconase, our lead compound, has been in clinical studies for other oncology indications and has proven itself to be well tolerated in over 1,000 patients treated to date.
Alfacell Corporation (Bloomfield, NJ; 973-748-8082), a leader in the research and development of ribonuclease enzymes with anti-cancer and other therapeutic proper-ties, announced the company has been issued new European Patent 837 878 that covers the amino acid sequence, method of manufacture, and a natural variant of its proprietary drug ONCONASE.
Shogen will continue as CEO, and will focus on the continued development of ONCONASE and Alfacell's other novel ribonuclease product candidates, including those from its cadre of amphinases, for other indications, as well as advancing the company's promising research in the microRNA, siRNA, and RNAi areas.